Skip to main content
. Author manuscript; available in PMC: 2019 Apr 26.
Published in final edited form as: J Clin Oncol. 2015 Aug 17;33(33):3911–3920. doi: 10.1200/JCO.2014.59.1503

Figure 2.

Figure 2

Impact of DNA repair pathway alterations and CKS1B copy number changes in myeloma. The prognostic impact of the number of copies of amp(1q) is greater than gain(1q) for both PFS (A) and OS (B). TP53 mutations and deletions are also associated with a significant negative impact on PFS (C) and OS (D). ATM and ATR mutations are associated with a worse outcome on both PFS (E) and OS (F).